Dendrite's SalesPlus Divisions Win Five Mid-Range Pharma Deals Including: Biodiphar, Baxter Healthcare.

Business Editors

MORRISTOWN, NJ--(BUSINESS WIRE)--March 30, 2000

Over 1000 New Pharma Reps To Be Equipped With Dendrite's Leading

Edge Technology

Dendrite International, Inc. (NASDAQ/NMS:DRTE) today announced that its SalesPlus divisions have signed five new agreements with pharmaceutical, biotech & medical device companies in the United States and in Europe. During the 1st quarter of 2000, SalesPlus won five of the six available contracts in this marketplace during the first quarter. This was in lieu of very strong competitive efforts from other vendors. These new customers reflect Dendrite's continuing focus in this marketplace.

The customers chose a variety of platforms from Dendrite's SalesPlus product and service offerings including Voyager's stand alone palm product and Catalyst's full solution capabilities with integrated support services and training. The variety of purpose-built products, each reflecting Dendrite's knowledge and skills, remains a major differentiater among customers making product choices in this marketplace.

"SalesPlus's products exemplify Dendrite's ability to supply clients from varying markets with tools specifically tailored to their individual company's needs," said John LaHaye, Senior Vice-President at SalesPlus. "The competition remains stiff, but we continue to demonstrate our ability to install and support customers, on-time, on-budget and with a product that provides real marketing advantages for the reps and their managers."

About Voyager

Voyager, a WinCE-based handheld application, is the ultra-portable solution, providing robust functionality rivaling many competitive laptop applications -- at a fraction of the cost and fully configured to the pharmaceutical, medical device, and biotech sales models. Operating in two-tier or three-tier mode, Voyager 3.0 delivers a streamlined and efficient method for remote sales reps to plan, profile and record all call activity with a minimum of effort.

About Catalyst

Catalyst provides a suite of comprehensive sales force effectiveness tools tailored to the specific needs of the pharmaceutical, medical device, biopharmaceutical and biotechnology companies. From account targeting and individual ROI analyses, to pre-call summaries and post-call reporting, to marketing encyclopedia information and sales process navigation, Catalyst offers a total solution for all users levels throughout sales and marketing organizations.

About Baxter HealthCare

Baxter International Inc. is a global medical products and services company that focuses on providing critical therapies for people with life-threatening conditions. Baxter's products and services in blood therapies, cardiovascular medicine, medication delivery and renal therapy are used by health-care providers and their patients in 112 countries.

About Dendrite

As a leading global provider of highly specialized, integrated product and service offerings for the Pharmaceutical and Consumer Package Goods (CPG) industries, Dendrite supports corporate strategies for a sustained competitive advantage. Thousands of sales representatives and their managers from over 150 companies and 57 countries rely on Dendrite for a uniquely tailored combination of tools, information and skills to help them prepare for tomorrow's challenges and improve their sales success. Focusing strongly on outcomes, Dendrite combines its modular software products with specifically tailored coaching and support services. With a global infrastructure as its foundation, Dendrite's commitment to unparalleled service has been the hallmark of the business and the basis of strong customer loyalty since the Company's inception in 1986.

Headquartered in Morristown, New Jersey, Dendrite employs over 1300 people around the world. For more information, visit the Company's Web site at http://www.drte.com.

Note: Dendrite is a registered trademark of Dendrite International, Inc.

This press release contains statements that are forward-looking statements and discuss expectations about future events or outcomes with respect to Dendrite and its business, including statements regarding expected results for future periods. We believe these statements are within the scope of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and we intend that these statements be covered by the safe harbors created by such acts. The forward-looking statements are based on our current expectations, assumptions, estimates and projections about our company and the pharmaceutical and consumer packaged goods industries and involve risks and uncertainties. Accordingly, Dendrite's actual results may differ materially from the results discussed in or implied by such forward-looking statements. The risk factors that could cause actual results to differ from the results expressed or implied by these forward-looking statements include the following: (i) our business is heavily dependent on the pharmaceutical industry; (ii) our quarterly results of operations may fluctuate significantly and may not meet market expectations; (iii) our lengthy sales and implementation cycles make it difficult to predict our quarterly revenues; (iv) our fixed costs may lead to fluctuations in our quarterly operating results if revenues fall below expectations; (v) our business is affected by variations in our customers' budget cycles; (vi) our revenues would decline and our business would be adversely affected by the loss of one of our major customers; (vii) we may be unable to successfully introduce new products or respond to technological change; (viii) we are exposed to risks associated with the Year 2000 (for example, (a) demand for our software products and services may decline before and after the Year 2000, (b) our Year 2000 remediation efforts may be unsuccessful and (c) we may incur material expenses in connection with any claim relating to Year 2000 compliance of our own products or the products of third parties); (ix) increased competition may result in price reductions and decreased demand for our products and services; (x) some of our customers rely on our competitors for market data; (xi) our international operations have risks that our domestic operations do not; (xii) our success depends on retaining our key senior management team and on attracting and retaining qualified personnel; (xiii) our inability to manage our growth could adversely affect our business; (xiv) our business depends on proprietary technology that we may not be to protect completely; and (xv) the consumer packaged goods industry may have different characteristics from those we are used to in the pharmaceutical industry. In light of the significant uncertainties inherent in these forward-looking statements, you should not consider their inclusion as a representation by us or anyone else that we will achieve our objectives and plans. Moreover, we assume no obligation to update these forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking statements. For further discussion of these and other factors that could adversely affect Dendrite's financial condition and results of operations consult Dendrite's annual report on Form 10-K and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission.